Elicio Therapeutics (ELTX) Expected to Post Quarterly Earnings on Thursday

Elicio Therapeutics (NASDAQ:ELTX) is expected to be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Elicio Therapeutics to announce earnings of ($0.53) per share for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Elicio Therapeutics (NASDAQ:ELTX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.16). On average, analysts expect Elicio Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Elicio Therapeutics Price Performance

ELTX stock opened at $2.86 on Tuesday. The firm’s 50-day moving average price is $6.02 and its two-hundred day moving average price is $8.74. Elicio Therapeutics has a 12-month low of $2.66 and a 12-month high of $16.00. The stock has a market capitalization of $54.60 million, a price-to-earnings ratio of -1.19 and a beta of 1.30. The company has a current ratio of 2.24, a quick ratio of 2.24 and a debt-to-equity ratio of 5.75.

Wall Street Analysts Forecast Growth

ELTX has been the subject of a number of analyst reports. B. Riley Financial began coverage on shares of Elicio Therapeutics in a report on Wednesday, June 10th. They set a “buy” rating and a $27.00 target price for the company. JonesTrading downgraded Elicio Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 16th. Weiss Ratings lowered Elicio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, July 29th. LADENBURG THALM/SH SH initiated coverage on Elicio Therapeutics in a report on Thursday, June 18th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, HC Wainwright lifted their price objective on Elicio Therapeutics from $17.00 to $23.00 and gave the stock a “buy” rating in a research report on Monday, June 15th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $19.75.

Hedge Funds Weigh In On Elicio Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada purchased a new position in shares of Elicio Therapeutics during the first quarter valued at approximately $225,000. Jane Street Group LLC purchased a new stake in shares of Elicio Therapeutics in the 1st quarter worth approximately $92,000. Geode Capital Management LLC increased its position in Elicio Therapeutics by 56.0% during the 2nd quarter. Geode Capital Management LLC now owns 120,831 shares of the company’s stock valued at $933,000 after buying an additional 43,364 shares in the last quarter. Raymond James Financial Inc. bought a new position in Elicio Therapeutics during the 2nd quarter valued at approximately $46,000. Finally, Vanguard Group Inc. increased its position in Elicio Therapeutics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 473,859 shares of the company’s stock valued at $5,184,000 after buying an additional 19,240 shares in the last quarter. Institutional investors own 35.03% of the company’s stock.

Elicio Therapeutics Company Profile

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.